Every Flavor Has a Story

I’ve always been curious, with a need to be on the cutting edge of scientific innovation, so after a successful academic career I moved to the rapidly evolving world of biotech. A 15-year journey in this space ultimately led me to Ultivue, their novel InSituPlex® assay, and following advances in tissue multiplexing.

As I approach my one-year anniversary with Ultivue, I am excited to be part of a vibrant, rapidly growing company committed to transforming anatomic pathology with our next generation staining technology, InSituPlex®.

The brilliant Stephen Hawking once said that “The universe does not behave according to our pre-conceived ideas. It continues to surprise us.” The same statement is also true for how we think of the dynamic nature of the cancer universe, in particular the complexity of the tumor immune microenvironment (TiME/TMEs)- an ever-evolving rich milieu comprising of non-malignant immune cells, fibroblasts, adipocytes, extracellular matrix components and neuronal cell types.

If you stand too close to the painting for too long observing all the details, you begin to lose sight of what those brush strokes have created. Only when you step back to take in the scene can you have a full understanding and appreciation for how the individual elements come together to create a work of art.

I have learned in my career that there is a special recipe for making young companies successful. You need to have an amazing product that enables customers to accomplish their goals in a better way than their current method.

It’s clearly a very timely discussion with many recent articles reviewing the complexities of the tumor microenvironment and overall tumor heterogeneity that have been implicated in late-stage clinical failures, underscoring an urgent need for tests that accurately predict response to the growing number of available therapies.

It is clear that “zoom fatigue” has set in, and some of the novelty of virtual conferences has worn off in the past year; having said that, they are likely here to stay, even as in-person events return with hybrid events in 2022.

Alfred Hitchcock once said, “The more successful the villain, the more successful the picture”, for the immunotherapy picture, that successful villain is M1 macrophages.